Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.86 |
| ▸ | RCOR1 | Q9UKL0 | 2/20 | 0.86 |
| ▸ | LDHB | P07195 | 4/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | TERF2IP | Q9NYB0 | 2/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.37 |
| ▸ | NPY2R | P49146 | 1/20 | 0.37 |
| ▸ | NPY4R | P50391 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.36 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.36 |
| ▸ | TERF2 | Q15554 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17793343 | 0.93 | KDM1A (0.90) | KDM1ARCOR1LDHBF11TERF2IP | |
| SCHEMBL21474053 | 0.93 | KDM1A (0.90) | KDM1ARCOR1LDHBF11TERF2IP | |
| Polymyxin B2 SCHEMBL15887064 | 0.92 | KDM1A (1.00) | KDM1ARCOR1LDHBF11TERF2IP | |
| Polymyxin B2 SCHEMBL534885 | 0.92 | KDM1A (1.00) | KDM1ARCOR1LDHBF11TERF2IP | |
| SCHEMBL21474126 | 0.92 | KDM1A (0.89) | KDM1ARCOR1LDHBF11TERF2IP | |
| Colistin B SCHEMBL1860364 | 0.91 | KDM1A (0.90) | KDM1ARCOR1LDHBF11TERF2IP | |
| SCHEMBL21474096 | 0.91 | KDM1A (0.89) | KDM1ARCOR1LDHBF11TERF2IP | |
| SCHEMBL21474087 | 0.91 | KDM1A (0.89) | KDM1ARCOR1LDHBF11TERF2IP | |
| SCHEMBL21504123 | 0.90 | KDM1A (0.95) | KDM1ARCOR1LDHBTERF2IPSSTR2 | |
| SCHEMBL21504375 | 0.90 | KDM1A (0.95) | KDM1ARCOR1LDHBTERF2IPSSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | Shanghai MICURX Pharmaceuticals Co., Ltd. (CN) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141981-A1 | NOVEL COMPOUNDS AND COMPOSITION FOR TARGETED THERAPY OF KIDNEY-ASSOCIATED CANCERS | GLS, ATP6V1B1, KRAS | KDM1A 3592/4885RCOR1 4682/4885LDHB 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.